You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSufentanil
Accession NumberDB00708  (APRD00671)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAn opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. [PubChem]
Structure
Thumb
Synonyms
N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide
N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide
Sufentanil
Sufentanilo
Sufentanilum
Sufentanyl
External Identifiers
  • R 30730
  • R 33800
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sufenta Inj 50mcg/mlliquid50 mcgintravenous; epiduralJanssen Inc1985-12-312007-11-26Canada
Sufenta Inj 50mcg/mlliquid50 mcgintravenousJanssen Pharmaceutica, Division Of Janssen Ortho Inc.1985-12-311996-09-10Canada
Sufentanil Citrateinjection50 ug/mLepidural; intravenousAkorn, Inc.2010-12-01Not applicableUs
Sufentanil Citrate Injection USPsolution50 mcgintravenous; epiduralSandoz Canada Incorporated2001-08-01Not applicableCanada
ZalvisoSublingual tablet15 μgSublingual useGrunenthal Gmb H2015-09-18Not applicableEu
ZalvisoSublingual tablet15 μgSublingual useGrunenthal Gmb H2015-09-18Not applicableEu
ZalvisoSublingual tablet15 μgSublingual useGrunenthal Gmb H2015-09-18Not applicableEu
ZalvisoSublingual tablet15 μgSublingual useGrunenthal Gmb H2015-09-18Not applicableEu
ZalvisoSublingual tablet15 μgSublingual useGrunenthal Gmb H2015-09-18Not applicableEu
ZalvisoSublingual tablet15 μgSublingual useGrunenthal Gmb H2015-09-18Not applicableEu
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sufentanil Citrateinjection, solution50 ug/mLepidural; intravenousHospira, Inc.1996-12-11Not applicableUs
Sufentanil Citrateinjection.05 mg/mLepidural; intravenousWest Ward Pharmaceutical Corp.1995-12-15Not applicableUs
Sufentanil Citrateinjection, solution50 ug/mLepidural; intravenousHospira, Inc.1996-12-11Not applicableUs
Sufentanil Citrateinjection.05 mg/mLepidural; intravenousWest Ward Pharmaceutical Corp.1995-12-15Not applicableUs
Sufentanil Citrateinjection.05 mg/mLepidural; intravenousWest Ward Pharmaceutical Corp.1995-12-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ChronogesicDURECT
DisufenAngenerico
FastfenCristália
SufentaJanssen
Sufenta ForteJanssen
Sufenta miteJanssen
SufentilClaris Lifesciences Ltd.
ZuftilPisa
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Sufentanil Citrate
Thumb
  • InChI Key: OJCZPLDERGDQRJ-UHFFFAOYSA-N
  • Monoisotopic Mass: 578.229801514
  • Average Mass: 578.674
DBSALT000275
Categories
UNIIAFE2YW0IIZ
CAS number56030-54-7
WeightAverage: 386.551
Monoisotopic: 386.202798904
Chemical FormulaC22H30N2O2S
InChI KeyInChIKey=GGCSSNBKKAUURC-UHFFFAOYSA-N
InChI
InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3
IUPAC Name
N-[4-(methoxymethyl)-1-[2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropanamide
SMILES
CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as anilides. These are organic heterocyclic compounds derived from oxoacids RkE(=O)l(OH)m (l not 0) by replacing an OH group by the NHPh group or derivative formed by ring substitution.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassAnilides
Direct ParentAnilides
Alternative Parents
Substituents
  • Anilide
  • Aralkylamine
  • 4-aminopiperidine
  • Piperidine
  • Heteroaromatic compound
  • Thiophene
  • Tertiary carboxylic acid amide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed as an analgesic adjunct in anesthesia and as a primary anesthetic drug in procedures requiring assisted ventilation and in the relief of pain.
PharmacodynamicsSufentanil is a synthetic opioid analgesic. Sufentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Sufentanil may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Sufentanil depresses the respiratory centers, depresses the cough reflex, and constricts the pupils.
Mechanism of actionOpiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Sufentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids open calcium-dependent inwardly rectifying potassium channels (OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life265 minutes
ClearanceNot Available
ToxicityLD50: 18.7 mg/kg (IV in mice)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Sufentanil Action PathwayDrug actionSMP00417
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9875
Blood Brain Barrier+0.9886
Caco-2 permeable+0.5201
P-glycoprotein substrateSubstrate0.6673
P-glycoprotein inhibitor IInhibitor0.8275
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterNon-inhibitor0.5594
CYP450 2C9 substrateNon-substrate0.7923
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.713
CYP450 1A2 substrateNon-inhibitor0.8954
CYP450 2C9 inhibitorNon-inhibitor0.7839
CYP450 2D6 inhibitorNon-inhibitor0.8416
CYP450 2C19 inhibitorNon-inhibitor0.5438
CYP450 3A4 inhibitorInhibitor0.6293
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6401
Ames testNon AMES toxic0.7695
CarcinogenicityNon-carcinogens0.8861
BiodegradationNot ready biodegradable0.9724
Rat acute toxicity3.0968 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9793
hERG inhibition (predictor II)Inhibitor0.772
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Akorn inc
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Liquidintravenous50 mcg
Liquidintravenous; epidural50 mcg
Injectionepidural; intravenous.05 mg/mL
Injectionepidural; intravenous50 ug/mL
Injection, solutionepidural; intravenous50 ug/mL
Solutionintravenous; epidural50 mcg
Sublingual tabletSublingual use15 μg
Prices
Unit descriptionCostUnit
Sufentanil citrate powder18927.0USD g
Sufenta 50 mcg/ml ampul5.38USD ml
Sufentanil 50 mcg/ml ampul3.92USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point97 °CPhysProp
water solubility76 mg/L (at 25 °C)ROY,SD & FLYNN,GL (1988)
logP3.95SANGSTER (1993)
logS-3.71ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.012 mg/mLALOGPS
logP3.4ALOGPS
logP3.61ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)8.86ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area32.78 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity111.42 m3·mol-1ChemAxon
Polarizability43.85 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Jacob Mathew, J. Killgore, “New methods for the synthesis of alfentanil, sufentanil, and remifentanil.” U.S. Patent US20060149071, issued July 06, 2006.

US20060149071
General ReferencesNot Available
External Links
ATC CodesN01AH03
AHFS Codes
  • 28:08.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (47.6 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Sufentanil.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Sufentanil.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Sufentanil is combined with 7-Nitroindazole.
AcebutololSufentanil may increase the bradycardic activities of Acebutolol.
AcepromazineAcepromazine may increase the hypotensive activities of Sufentanil.
AcepromazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Sufentanil.
adipiplonThe risk or severity of adverse effects can be increased when Sufentanil is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Alfentanil.
AlimemazineAlimemazine may increase the hypotensive activities of Sufentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sufentanil.
AlvimopanThe risk or severity of adverse effects can be increased when Sufentanil is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amiloride.
AmiodaroneSufentanil may increase the bradycardic activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Sufentanil which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amobarbital.
AmoxapineSufentanil may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Sufentanil.
AmperozideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Sufentanil.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Sufentanil.
AprepitantThe serum concentration of Sufentanil can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Sufentanil is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Asenapine.
AtazanavirThe metabolism of Sufentanil can be decreased when combined with Atazanavir.
AtenololAtenolol may increase the bradycardic activities of Sufentanil.
AtomoxetineThe metabolism of Sufentanil can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Sufentanil.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Sufentanil.
AzaperoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Azaperone.
AzelastineSufentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Sufentanil.
AzosemideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Sufentanil is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Sufentanil.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bendroflumethiazide.
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Sufentanil.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Sufentanil.
BenzocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the analgesic activities of Sufentanil.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Sufentanil is combined with Benzyl alcohol.
BeractantSufentanil may increase the bradycardic activities of Beractant.
BetaxololBetaxolol may increase the bradycardic activities of Sufentanil.
BexaroteneThe serum concentration of Sufentanil can be decreased when it is combined with Bexarotene.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Sufentanil.
BisoprololBisoprolol may increase the bradycardic activities of Sufentanil.
BoceprevirThe metabolism of Sufentanil can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Sufentanil can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Sufentanil can be decreased when it is combined with Bosentan.
BretyliumBretylium may increase the bradycardic activities of Sufentanil.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.
BrimonidineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sufentanil.
BuprenorphineBuprenorphine may decrease the analgesic activities of Sufentanil.
BuprenorphineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Sufentanil.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sufentanil.
ButacaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Sufentanil is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Butethal.
ButorphanolButorphanol may decrease the analgesic activities of Sufentanil.
ButorphanolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Butorphanol.
CalfactantSufentanil may increase the bradycardic activities of Calfactant.
Canrenoic acidThe risk or severity of adverse effects can be increased when Sufentanil is combined with Canrenoic acid.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Sufentanil.
CarbinoxamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Carisoprodol.
CarteololCarteolol may increase the bradycardic activities of Sufentanil.
CarvedilolSufentanil may increase the bradycardic activities of Carvedilol.
CeritinibSufentanil may increase the bradycardic activities of Ceritinib.
CeritinibThe serum concentration of Sufentanil can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sufentanil.
ChlormezanoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chloroprocaine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Sufentanil.
ChlorphentermineChlorphentermine may increase the analgesic activities of Sufentanil.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Sufentanil.
ChlorpromazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Sufentanil.
CitalopramSufentanil may increase the serotonergic activities of Citalopram.
ClarithromycinThe metabolism of Sufentanil can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Sufentanil can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Sufentanil is combined with clomethiazole.
ClomipramineSufentanil may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Sufentanil.
ClonazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clonazepam.
ClonidineClonidine may increase the bradycardic activities of Sufentanil.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sufentanil.
ClotrimazoleThe metabolism of Sufentanil can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Sufentanil.
CobicistatThe metabolism of Sufentanil can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Sufentanil.
ConivaptanThe serum concentration of Sufentanil can be increased when it is combined with Conivaptan.
ConivaptanThe risk or severity of adverse effects can be increased when Sufentanil is combined with Conivaptan.
CrizotinibThe metabolism of Sufentanil can be decreased when combined with Crizotinib.
CrizotinibSufentanil may increase the bradycardic activities of Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclobenzaprine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Sufentanil.
CyclosporineThe metabolism of Sufentanil can be decreased when combined with Cyclosporine.
CyclothiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyproheptadine.
DabrafenibThe serum concentration of Sufentanil can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sufentanil.
DapoxetineSufentanil may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Sufentanil.
DarunavirThe metabolism of Sufentanil can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Sufentanil can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Sufentanil can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Sufentanil can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Sufentanil is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Sufentanil.
DesmopressinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Detomidine.
DexamethasoneThe serum concentration of Sufentanil can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Sufentanil.
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Sufentanil.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Sufentanil.
DextromoramideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sufentanil.
DezocineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Diazepam.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Sufentanil.
DifenoxinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Difenoxin.
DigoxinDigoxin may increase the bradycardic activities of Sufentanil.
DihydrocodeineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Sufentanil can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydromorphine.
DiltiazemThe metabolism of Sufentanil can be decreased when combined with Diltiazem.
DiltiazemSufentanil may increase the bradycardic activities of Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenoxylate.
DonepezilSufentanil may increase the bradycardic activities of Donepezil.
DoramectinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Doxepin.
DoxycyclineThe metabolism of Sufentanil can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.
DoxylamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Sufentanil is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.
DronedaroneThe metabolism of Sufentanil can be decreased when combined with Dronedarone.
DronedaroneSufentanil may increase the bradycardic activities of Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Sufentanil.
DrospirenoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sufentanil.
EcgonineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Sufentanil is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Sufentanil can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Sufentanil is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Efonidipine.
EluxadolineSufentanil may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Sufentanil.
EntacaponeThe risk or severity of adverse effects can be increased when Sufentanil is combined with Entacapone.
EnzalutamideThe serum concentration of Sufentanil can be decreased when it is combined with Enzalutamide.
EplerenoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Eplerenone.
ErythromycinThe metabolism of Sufentanil can be decreased when combined with Erythromycin.
EscitalopramSufentanil may increase the serotonergic activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Sufentanil can be decreased when it is combined with Eslicarbazepine acetate.
EsmololEsmolol may increase the bradycardic activities of Sufentanil.
EstazolamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sufentanil.
Etacrynic acidThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etacrynic acid.
EthanolSufentanil may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Sufentanil.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sufentanil.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Sufentanil.
EthosuximideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Sufentanil.
EtoperidoneSufentanil may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etorphine.
EtravirineThe serum concentration of Sufentanil can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fencamfamine.
FenfluramineSufentanil may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fentanyl.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Sufentanil.
FexofenadineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fexofenadine.
FingolimodSufentanil may increase the bradycardic activities of Fingolimod.
FlibanserinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flibanserin.
FluconazoleThe metabolism of Sufentanil can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flunitrazepam.
FluoxetineSufentanil may increase the serotonergic activities of Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flupentixol.
FluphenazineFluphenazine may increase the hypotensive activities of Sufentanil.
FluphenazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sufentanil.
FluspirileneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fluticasone Propionate.
FluvoxamineSufentanil may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe metabolism of Sufentanil can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Sufentanil can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Sufentanil can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fospropofol.
FurosemideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Furosemide.
Fusidic AcidThe serum concentration of Sufentanil can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Sufentanil is combined with gabapentin enacarbil.
GalantamineGalantamine may increase the bradycardic activities of Sufentanil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Sufentanil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Sufentanil is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Glutethimide.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Sufentanil.
GuanfacineSufentanil may increase the bradycardic activities of Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sufentanil.
HalothaneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Sufentanil.
HexobarbitalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hexobarbital.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Sufentanil.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hydrocodone.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sufentanil.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Sufentanil.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.
HydroxyzineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Sufentanil.
IdelalisibThe serum concentration of Sufentanil can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Iloperidone.
ImatinibThe metabolism of Sufentanil can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Imipramine.
IndalpineSufentanil may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Indapamide.
IndinavirThe metabolism of Sufentanil can be decreased when combined with Indinavir.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Sufentanil.
IsavuconazoniumThe metabolism of Sufentanil can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Isoflurane.
IsosorbideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Isosorbide.
IsradipineThe metabolism of Sufentanil can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Sufentanil can be decreased when combined with Itraconazole.
IvabradineSufentanil may increase the bradycardic activities of Ivabradine.
IvacaftorThe serum concentration of Sufentanil can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ketobemidone.
KetoconazoleThe metabolism of Sufentanil can be decreased when combined with Ketoconazole.
KW-3902The risk or severity of adverse effects can be increased when Sufentanil is combined with KW-3902.
LabetalolLabetalol may increase the bradycardic activities of Sufentanil.
LacosamideSufentanil may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LamotrigineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lamotrigine.
LanreotideSufentanil may increase the bradycardic activities of Lanreotide.
LevetiracetamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levetiracetam.
LevobunololSufentanil may increase the bradycardic activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levomethadyl Acetate.
LevomilnacipranSufentanil may increase the serotonergic activities of Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Sufentanil.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Sufentanil.
LithiumThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lofentanil.
LopinavirThe metabolism of Sufentanil can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sufentanil.
LovastatinThe metabolism of Sufentanil can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Sufentanil.
Lu AA21004Sufentanil may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Sufentanil.
LucinactantSufentanil may increase the bradycardic activities of Lucinactant.
LuliconazoleThe serum concentration of Sufentanil can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Sufentanil.
MeclizineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Sufentanil is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Sufentanil.
MepivacaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sufentanil.
MersalylThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Sufentanil.
MesoridazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Sufentanil.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methadyl Acetate.
MethamphetamineMethamphetamine may increase the analgesic activities of Sufentanil.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Sufentanil.
MethapyrileneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Sufentanil.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Sufentanil.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methyclothiazide.
MethyldopaSufentanil may increase the bradycardic activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Sufentanil.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methylphenobarbital.
MetipranololSufentanil may increase the bradycardic activities of Metipranolol.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Sufentanil.
MetolazoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Metolazone.
MetoprololMetoprolol may increase the bradycardic activities of Sufentanil.
MetyrosineSufentanil may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Sufentanil.
MifepristoneThe metabolism of Sufentanil can be decreased when combined with Mifepristone.
MilnacipranSufentanil may increase the serotonergic activities of Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.
MirtazapineSufentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Sufentanil.
MitotaneThe serum concentration of Sufentanil can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Sufentanil can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Sufentanil.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Sufentanil.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Sufentanil.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.
NabiloneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nabilone.
NadololSufentanil may increase the bradycardic activities of Nadolol.
NafcillinThe serum concentration of Sufentanil can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may decrease the analgesic activities of Sufentanil.
NalbuphineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nalbuphine.
NaltrexoneThe therapeutic efficacy of Sufentanil can be decreased when used in combination with Naltrexone.
NebivololSufentanil may increase the bradycardic activities of Nebivolol.
NefazodoneThe metabolism of Sufentanil can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Sufentanil can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Sufentanil can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Sufentanil can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Sufentanil can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Sufentanil.
OctreotideOctreotide may increase the bradycardic activities of Sufentanil.
OlanzapineSufentanil may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sufentanil.
OlaparibThe metabolism of Sufentanil can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Sufentanil is combined with Opium.
OrphenadrineSufentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Sufentanil.
OsanetantThe risk or severity of adverse effects can be increased when Sufentanil is combined with Osanetant.
OsimertinibThe serum concentration of Sufentanil can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxybuprocaine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Sufentanil.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sufentanil.
OxymorphoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Sufentanil.
PalbociclibThe serum concentration of Sufentanil can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Paliperidone.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Sufentanil.
ParaldehydeSufentanil may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Sufentanil.
ParoxetineSufentanil may increase the serotonergic activities of Paroxetine.
PasireotideSufentanil may increase the bradycardic activities of Pasireotide.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Sufentanil.
PenbutololSufentanil may increase the bradycardic activities of Penbutolol.
PentazocinePentazocine may decrease the analgesic activities of Sufentanil.
PentazocineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Sufentanil.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Sufentanil.
PerampanelThe risk or severity of adverse effects can be increased when Sufentanil is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Sufentanil is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Sufentanil.
PerphenazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Sufentanil.
PhenobarbitalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Phenoxyethanol.
PhenterminePhentermine may increase the analgesic activities of Sufentanil.
PhenytoinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pimozide.
PindololSufentanil may increase the bradycardic activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Sufentanil.
PipotiazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Sufentanil.
PiretanideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Piretanide.
PizotifenThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pomalidomide.
Poractant alfaSufentanil may increase the bradycardic activities of Poractant alfa.
PosaconazoleThe metabolism of Sufentanil can be decreased when combined with Posaconazole.
PotassiumThe risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium Citrate.
PramipexoleSufentanil may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sufentanil.
PrilocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Procaine.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Sufentanil.
ProchlorperazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Sufentanil.
PromazinePromazine may increase the hypotensive activities of Sufentanil.
PromazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Sufentanil.
PromethazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Promethazine.
PropafenoneSufentanil may increase the bradycardic activities of Propafenone.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Sufentanil.
ProparacaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Propoxycaine.
PropranololPropranolol may increase the bradycardic activities of Sufentanil.
ProtriptylineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Sufentanil is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quetiapine.
QuinethazoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Sufentanil.
RamelteonThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ramelteon.
RamosetronSufentanil may increase the constipating activities of Ramosetron.
RanolazineThe metabolism of Sufentanil can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sufentanil.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Sufentanil.
RifabutinThe metabolism of Sufentanil can be increased when combined with Rifabutin.
RifampicinThe metabolism of Sufentanil can be increased when combined with Rifampicin.
RifapentineThe metabolism of Sufentanil can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Risperidone.
RitonavirThe metabolism of Sufentanil can be decreased when combined with Ritonavir.
RivastigmineSufentanil may increase the bradycardic activities of Rivastigmine.
RomifidineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Romifidine.
RopiniroleSufentanil may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sufentanil.
RotigotineSufentanil may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Sufentanil.
RuxolitinibRuxolitinib may increase the bradycardic activities of Sufentanil.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Sufentanil is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Sufentanil can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sufentanil.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Sufentanil.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sufentanil.
SertindoleThe risk or severity of adverse effects can be increased when Sufentanil is combined with Sertindole.
SertralineSufentanil may increase the serotonergic activities of Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Sevoflurane.
SildenafilThe metabolism of Sufentanil can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Sufentanil can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Sufentanil can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Sufentanil.
SotalolSotalol may increase the bradycardic activities of Sufentanil.
SpironolactoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Spironolactone.
St. John's WortThe serum concentration of Sufentanil can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Sufentanil.
SulfisoxazoleThe metabolism of Sufentanil can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Sufentanil.
SuvorexantThe risk or severity of adverse effects can be increased when Sufentanil is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tasimelteon.
TelaprevirThe metabolism of Sufentanil can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Sufentanil can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Sufentanil.
TetrabenazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrodotoxin.
ThalidomideSufentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Sufentanil.
TheobromineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Sufentanil.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Sufentanil.
ThioridazineThioridazine may increase the hypotensive activities of Sufentanil.
ThioridazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tiagabine.
TiclopidineThe metabolism of Sufentanil can be decreased when combined with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tiletamine.
TimololTimolol may increase the bradycardic activities of Sufentanil.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Sufentanil.
TizanidineTizanidine may increase the bradycardic activities of Sufentanil.
TocilizumabThe serum concentration of Sufentanil can be decreased when it is combined with Tocilizumab.
TofacitinibTofacitinib may increase the bradycardic activities of Sufentanil.
TolcaponeThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Sufentanil.
TolvaptanThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Sufentanil.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tranylcypromine.
TrazodoneSufentanil may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Sufentanil.
TriamtereneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triazolam.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Sufentanil.
TrifluoperazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Sufentanil.
TriflupromazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Sufentanil.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Sufentanil.
TrimipramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Sufentanil.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Sufentanil.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Sufentanil.
UlaritideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Sufentanil.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Sufentanil.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Sufentanil.
VenlafaxineThe metabolism of Sufentanil can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Sufentanil can be decreased when combined with Verapamil.
VerapamilSufentanil may increase the bradycardic activities of Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Vigabatrin.
VilazodoneSufentanil may increase the serotonergic activities of Vilazodone.
VoriconazoleThe metabolism of Sufentanil can be decreased when combined with Voriconazole.
VortioxetineSufentanil may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Sufentanil.
XylazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ziconotide.
ZimelidineSufentanil may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe metabolism of Sufentanil can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Sufentanil.
ZonisamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Hurle MA: Changes in the expression of G protein-coupled receptor kinases and beta-arrestin 2 in rat brain during opioid tolerance and supersensitivity. J Neurochem. 2001 Apr;77(2):486-92. [PubMed:11299311 ]
  2. Levron JC: [Pharmacokinetics and pharmacodynamics of morphinomimetics in the central nervous system]. Agressologie. 1991;32(6-7):318-20. [PubMed:1688220 ]
  3. Ilien B, Galzi JL, Mejean A, Goeldner M, Hirth C: A mu-opioid receptor-filter assay. Rapid estimation of binding affinity of ligands and reversibility of long-lasting ligand-receptor complexes. Biochem Pharmacol. 1988 Oct 15;37(20):3843-51. [PubMed:2847746 ]
  4. Colpaert FC, Leysen JE, Michiels M, van den Hoogen RH: Epidural and intravenous sufentanil in the rat: analgesia, opiate receptor binding, and drug concentrations in plasma and brain. Anesthesiology. 1986 Jul;65(1):41-9. [PubMed:3014923 ]
  5. Leysen JE, Gommeren W: In vitro binding properties of 3H-sufentanil, a superior ligand for the mu-opiate receptor. Arch Int Pharmacodyn Ther. 1982 Dec;260(2):287-9. [PubMed:6131653 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Freye E, Latasch L, Portoghese PS: The delta receptor is involved in sufentanil-induced respiratory depression--opioid subreceptors mediate different effects. Eur J Anaesthesiol. 1992 Nov;9(6):457-62. [PubMed:1330549 ]
  2. Zhu J, Xue JC, Law PY, Claude PA, Luo LY, Yin J, Chen C, Liu-Chen LY: The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor. FEBS Lett. 1996 Apr 15;384(2):198-202. [PubMed:8612823 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Zhu J, Xue JC, Law PY, Claude PA, Luo LY, Yin J, Chen C, Liu-Chen LY: The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor. FEBS Lett. 1996 Apr 15;384(2):198-202. [PubMed:8612823 ]
  2. Chang HM, Berde CB, Holz GG 4th, Steward GF, Kream RM: Sufentanil, morphine, met-enkephalin, and kappa-agonist (U-50,488H) inhibit substance P release from primary sensory neurons: a model for presynaptic spinal opioid actions. Anesthesiology. 1989 Apr;70(4):672-7. [PubMed:2467589 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23